Pharmaceutical

CT-080 by First Condor Group for Esophageal Cancer: Likelihood of Approval

CT-080 is under clinical development by First Condor Group and currently in Phase II for Esophageal Cancer.

Oct 3, 2023 - 20:00
CT-080 is under clinical development by First Condor Group and currently in Phase II for Esophageal Cancer.
Read the original article

Tags:

Previous Article

BW-20507 by Argo Biopharma Australia for Hepatitis B: Likelihood of Approval

Next Article

CT-080 by First Condor Group for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

China NMPA grants IND clearance for Fermion’s TYK2 JH2 inhibitor

China NMPA grants IND clearance for Fermion’s TYK2 JH2 ...

Feb 6, 2024

Alfasigma to buy Intercept Pharmaceuticals for $794m

Alfasigma to buy Intercept Pharmaceuticals for $794m

Sep 27, 2023

EU agencies back Covid-19 vaccine update ahead of autumn campaign

EU agencies back Covid-19 vaccine update ahead of autum...

Jun 7, 2023